Cannara Biotech Inc. (TSX:LOVE)
Canada
· Delayed Price · Currency is CAD 1.770
-0.010 (-0.56%)
Apr 28, 2026, 3:55 PM EST
Cannara Biotech Income Statement
Financials in millions CAD. Fiscal year is September - August.
Millions CAD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '26 Feb 28, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | 2020 - 2018 |
| Operating Revenue | 112.67 | 106.86 | 81.65 | 57.07 | 35.48 | 16.29 | Upgrade
|
| Other Revenue | 0.34 | 0.34 | 0.09 | 0.19 | 0.36 | 0.73 | Upgrade
|
| Revenue | 113.01 | 107.2 | 81.75 | 57.26 | 35.84 | 17.02 | Upgrade
|
| Revenue Growth (YoY) | 20.14% | 31.14% | 42.77% | 59.76% | 110.58% | 567.25% | Upgrade
|
| Cost of Revenue | 65.01 | 60.1 | 51.96 | 30.03 | 18.51 | 6.72 | Upgrade
|
| Gross Profit | 48 | 47.1 | 29.79 | 27.23 | 17.33 | 10.3 | Upgrade
|
| Selling, General & Admin | 24.21 | 21.98 | 17.67 | 11.77 | 9.68 | 6.98 | Upgrade
|
| Research & Development | 1.06 | 0.71 | 1.12 | 1.03 | 1.26 | 1.91 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | 1.56 | 1.38 | 0.96 | 1.23 | 1.03 | Upgrade
|
| Operating Expenses | 30.17 | 25.44 | 22.14 | 15.51 | 12.51 | 10.24 | Upgrade
|
| Operating Income | 17.83 | 21.66 | 7.64 | 11.72 | 4.82 | 0.05 | Upgrade
|
| Interest Expense | -2.82 | -3.77 | -4.85 | -4.74 | -2.23 | -1.71 | Upgrade
|
| Interest & Investment Income | 0.32 | 0.28 | 0.18 | 0.24 | 0.09 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.02 | -0 | -0.12 | 0.07 | 0.03 | -0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.57 | -0.59 | -0.82 | -0.56 | -0.53 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | 14.78 | 17.59 | 2.04 | 6.72 | 2.18 | -1.73 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.3 | 0.42 | 2.03 | -0.13 | -0.05 | -0.07 | Upgrade
|
| Other Unusual Items | 0.11 | 0.09 | 0.41 | 0.36 | 0.17 | 0.27 | Upgrade
|
| Pretax Income | 15.19 | 18.1 | 4.48 | 6.95 | 2.31 | -1.53 | Upgrade
|
| Income Tax Expense | 5.04 | 5.02 | -1.95 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 10.16 | 13.08 | 6.44 | 6.95 | 2.31 | -1.53 | Upgrade
|
| Net Income | 10.16 | 13.08 | 6.44 | 6.95 | 2.31 | -1.53 | Upgrade
|
| Net Income to Common | 10.16 | 13.08 | 6.44 | 6.95 | 2.31 | -1.53 | Upgrade
|
| Net Income Growth | -24.18% | 103.09% | -7.30% | 201.26% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 93 | 91 | 90 | 89 | 88 | 77 | Upgrade
|
| Shares Outstanding (Diluted) | 95 | 92 | 91 | 90 | 88 | 77 | Upgrade
|
| Shares Change (YoY) | 3.00% | 1.08% | 1.83% | 2.16% | 14.80% | 7.26% | Upgrade
|
| EPS (Basic) | 0.11 | 0.14 | 0.07 | 0.08 | 0.03 | -0.02 | Upgrade
|
| EPS (Diluted) | 0.11 | 0.14 | 0.07 | 0.08 | 0.03 | -0.10 | Upgrade
|
| EPS Growth | -21.69% | 100.00% | -10.00% | 195.77% | - | - | Upgrade
|
| Free Cash Flow | 16.11 | 13.65 | 3.21 | -3.97 | -21.55 | -33.17 | Upgrade
|
| Free Cash Flow Per Share | 0.17 | 0.15 | 0.04 | -0.04 | -0.24 | -0.43 | Upgrade
|
| Gross Margin | 42.47% | 43.94% | 36.44% | 47.56% | 48.35% | 60.49% | Upgrade
|
| Operating Margin | 15.78% | 20.20% | 9.35% | 20.46% | 13.45% | 0.31% | Upgrade
|
| Profit Margin | 8.99% | 12.20% | 7.88% | 12.13% | 6.43% | -8.98% | Upgrade
|
| Free Cash Flow Margin | 14.26% | 12.74% | 3.93% | -6.93% | -60.11% | -194.86% | Upgrade
|
| EBITDA | 23.94 | 28.06 | 13.74 | 16.53 | 8.62 | 2.75 | Upgrade
|
| EBITDA Margin | 21.18% | 26.18% | 16.81% | 28.87% | 24.06% | 16.18% | Upgrade
|
| D&A For EBITDA | 6.11 | 6.4 | 6.1 | 4.82 | 3.8 | 2.7 | Upgrade
|
| EBIT | 17.83 | 21.66 | 7.64 | 11.72 | 4.82 | 0.05 | Upgrade
|
| EBIT Margin | 15.78% | 20.20% | 9.35% | 20.46% | 13.45% | 0.31% | Upgrade
|
| Effective Tax Rate | 33.15% | 27.74% | - | - | - | - | Upgrade
|
| Revenue as Reported | 112.95 | 107.32 | 82.15 | 57.56 | 36 | 17.27 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.